1. Home
  2. RMNI vs EDIT Comparison

RMNI vs EDIT Comparison

Compare RMNI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rimini Street Inc. (DE)

RMNI

Rimini Street Inc. (DE)

HOLD

Current Price

$4.09

Market Cap

383.7M

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.49

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMNI
EDIT
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.7M
432.8M
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
RMNI
EDIT
Price
$4.09
$2.49
Analyst Decision
Strong Buy
Buy
Analyst Count
4
13
Target Price
★ $7.00
$6.10
AVG Volume (30 Days)
287.8K
★ 2.3M
Earning Date
10-29-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 197.50
37.50
EPS
★ 0.04
N/A
Revenue
★ $431,496,000.00
$31,937,000.00
Revenue This Year
$4.95
N/A
Revenue Next Year
$5.58
N/A
P/E Ratio
$103.38
★ N/A
Revenue Growth
5.33
★ 132.64
52 Week Low
$2.87
$1.66
52 Week High
$5.68
$3.94

Technical Indicators

Market Signals
Indicator
RMNI
EDIT
Relative Strength Index (RSI) 39.69 44.31
Support Level $4.02 $2.31
Resistance Level $4.14 $2.87
Average True Range (ATR) 0.12 0.21
MACD 0.02 -0.01
Stochastic Oscillator 26.56 30.34

Price Performance

Historical Comparison
RMNI
EDIT

About RMNI Rimini Street Inc. (DE)

Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: